Search for: "Price v. Holman"
Results 41 - 44
of 44
Sorted by Relevance
|
Sort by Date
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging… [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its… [read post]
6 Mar 2024, 9:03 pm
In addition, if a company uses transition plans, scenario analysis, or internal carbon prices to manage a material climate-related risk, the final rules require disclosures about such use. [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in… [read post]
